Please login to the form below
Cellectis
This page shows the latest Cellectis news and features for those working in and with pharma, biotech and healthcare.
Gilead signs $3bn-plus gene-editing deal with Sangamo
The deal with Sangamo means rivals in the CAR-T category such asand off-the-shelf specialist Cellectis won’t be able to use the ZFN technology in their own ... Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’favoured
Latest news
-
Cellectis floored by patient death in CAR-T trial
Cellectis floored by patient death in CAR-T trial. FDA puts two cancer immunotherapy trials on hold. ... It may be that the FDA will exercise greater caution in Cellectis' case.
-
Servier cleared to start US trials CAR-T therapy
The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Cellectis specialises in the development of ‘off-the-shelf’CAR-T
-
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial. Investigational New Drug gets go-ahead for trials in patients with two haematological cancers. ... This is not the first time that one of Cellectis' CAR-T candidates has been tested in patients
-
Juno cleared to restart CAR-T trial after deaths
The green light is a relief to Juno but could raise a warning flag for other companies developing CAR-T therapies, which includeand Cellectis, among others.
-
Chinese biotech claims 90% cure rate for CAR-T therapy
Other recent deals include Pfizer and Servier's collaboration with Cellectis - signed last November - as well as Merck &Co's $941m alliance with Intrexon, Amgen's $1bn collaboration with Kite Pharma
More from news
Approximately 8 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2015
379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.
-
Pharma deals in May 2015
Following the collaboration announced in June 2014 with Cellectis, the rumours are now going around that Pfizer may be planning an acquisition with an estimated price tag of $1.6bn.
-
Pharma deals in March 2015
Also Evaluate reports a cautious approach by big pharma. Novartis, J&J and Pfizer (via a deal with Cellectis) are in the go-kart race but other companies such as Merck
-
Pharma deals during June 2014
Cellectis has reserved 12 other targets and Pfizer will provide preclinical development assistance for four of these. ... easily. Cellectis plans to open a research site in the US to work more closely with Pfizer.
-
Deal Watch table for June 2014
350. Medreich/ Meiji Seika. Company acquisition. India-based manufacturing company. 290. Cellectis/ Pfizer.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Zelluna Immunotherapy appoints chief technology officer
Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.
-
Cellectis’ Mathieu Simon will serve as interim chief medical officer
Cellectis’ Mathieu Simon will serve as interim chief medical officer. He will take over the responsibilities of Loan Hoang-Sayag. ... Cellectis has appointed Mathieu Simon to as interim chief medical officer, taking over the role from Loan Hoan-Sayag,
-
Rainer Boehm and Hervé Hoppenot join Cellectics board
I see exciting opportunities for Cellectis to address unmet medical needs and make a meaningful difference in people’s lives. ... I am excited to be joining the Cellectis board during this important time of growth.”.
-
Dr Niall Murphy and Pierre Schwich join Pharnext
Meanwhile, Pierre Schwich (pictured left) joins Pharnext from Cellectis where he served as chief financial officer from 2011 until 2014. ... Before joining Cellectis, he served as chief financial officer and corporate secretary for Genesys Conferencing,
More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
- Project Manager, Medical Communications, London
-
Excellent Salary
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Account Manager – Med Comms – London
-
Salary TBC
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Senior Account Director, Healthcare Brand Communications, London
-
Excellent Package
-
Scientific Director
-
Great salary and bebefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Medical Writer, e-learning/ training, London
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and benefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Senior Programme Executive
-
Salary TBC
- Group Account Director, Healthcare Brand Communications, London
-
Excellent Package
Subscribe to our email news alerts
- BenevolentAI raises $115m to fund drug development
- Shire rebuffs Takeda bids, as Allergan bows out
- Abeona Therapeutics names CEO
- Zelluna Immunotherapy appoints chief technology officer
- Spirit Health Group offers new market access consultancy service
- Why heading online for scientific meetings can yield greater HCP engagement
PMHub
Digitas Health
Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....
Latest intelligence
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Quick links
Infographics
